0001209191-21-015487.txt : 20210301
0001209191-21-015487.hdr.sgml : 20210301
20210301201707
ACCESSION NUMBER: 0001209191-21-015487
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210225
FILED AS OF DATE: 20210301
DATE AS OF CHANGE: 20210301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shah Jatin
CENTRAL INDEX KEY: 0001782186
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36167
FILM NUMBER: 21700693
MAIL ADDRESS:
STREET 1: C/O KARYOPHARM THERAPEUTICS, INC.
STREET 2: 85 WELLS AVENUE
CITY: NEWTON
STATE: MA
ZIP: 02459
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Karyopharm Therapeutics Inc.
CENTRAL INDEX KEY: 0001503802
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 263931704
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
BUSINESS PHONE: 617-658-0600
MAIL ADDRESS:
STREET 1: 85 WELLS AVENUE
STREET 2: SECOND FLOOR
CITY: NEWTON
STATE: MA
ZIP: 02459
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-02-25
0
0001503802
Karyopharm Therapeutics Inc.
KPTI
0001782186
Shah Jatin
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVE.
NEWTON
MA
02459
0
1
0
0
EVP, Chief Medical Officer
Common Stock
2021-02-25
4
A
0
22013
0.00
A
107691
D
Stock Option (right to buy)
14.56
2021-02-25
4
A
0
59968
0.00
A
2031-02-24
Common Stock
59968
59968
D
Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 25, 2022.
The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 22,013 newly awarded RSUs, 33,887 RSUs previously reported in Table II, and 51,791 shares of common stock.
This option was granted on February 25, 2021 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 25, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter.
/s/ Nancy Smith as Attorney-in-Fact for Jatin Shah
2021-03-01